We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
Turnover
46.34%
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
-12.61%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.9B
AUM Growth
-$300M
(-9.4%)
Cap. Flow
+$207M
Cap. Flow
% of AUM
7.15%
Top 10 Holdings %
Top 10 Hldgs %
60.65%
Holding
101
New
14
Increased
15
Reduced
4
Closed
21
Avg Time Held Equity + Options
1
year
Top 10 Avg Time Held Equity + Options
1.3
years
Top 20 Avg Time Held Equity + Options
1.3
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
1.3
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$145M |
| 2 |
Arvinas
ARVN
|
+$81.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$58.7M |
| 4 |
Revolution Medicines
RVMD
|
+$58.5M |
| 5 |
Allogene Therapeutics
ALLO
|
+$39.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcus Biosciences
RCUS
|
+$103M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$41.2M |
| 3 |
Vaxcyte
PCVX
|
+$31.5M |
| 4 |
Bicycle Therapeutics
BCYC
|
+$24M |
| 5 |
Exelixis
EXEL
|
+$19.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.48% |
| 2 | Miscellaneous | 0.84% |
| 3 | Financials | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Orchestra BioMed
OBIO
$323M
| $3.98M | 0.14% |
400,000
| – | – |
2020 Q3
7 quarters
|
|
52
Erasca
ERAS
$4.69B
| $3.78M | 0.13% |
678,441
| – | – |
2021 Q3
3 quarters
|
|
53
LENZ Therapeutics
LENZ
$102M
| $3.2M | 0.11% |
166,026
+19,700
| +13% | +$439K |
2021 Q4
2 quarters
|
|
54
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $3.12M | 0.11% |
963,333
| – | – |
2021 Q1
5 quarters
|
|
55
PUT
Celldex Therapeutics
CLDX
$2.16B
| $3.11M | 0.11% |
+115,200
| New | +$3.35M |
2022 Q2
0 quarters
|
|
56
ARS Pharmaceuticals
SPRY
$398M
| $2.44M | 0.08% |
575,359
+245,822
| +75% | +$857K |
2020 Q4
6 quarters
|
|
57
Tempest Therapeutics
TPST
$10.7M
| $2.22M | 0.08% |
+79,328
| New | +$3.08M |
2022 Q2
0 quarters
|
|
|
KNTE
58
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $2.21M | 0.08% |
175,000
| – | – |
2020 Q4
6 quarters
|
|
|
EUCR
59
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
| $1.98M | 0.07% |
200,000
| – | – |
2021 Q1
5 quarters
|
|
|
BLSA
60
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $1.98M | 0.07% |
200,000
| – | – |
2020 Q4
6 quarters
|
|
|
FVAM
61
DELISTED
5:01 Acquisition Corp
FVAM
| $1.98M | 0.07% |
200,000
| – | – |
2020 Q4
6 quarters
|
|
62
DELISTED
Verve Therapeutics
VERV
| $1.51M | 0.05% |
98,593
| – | – |
2021 Q2
4 quarters
|
|
63
Dyne Therapeutics
DYN
$2.66B
| $1.48M | 0.05% |
215,000
| – | – |
2020 Q3
7 quarters
|
|
64
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $1.47M | 0.05% |
150,000
| – | – |
2021 Q1
5 quarters
|
|
65
Olema Pharmaceuticals
OLMA
$569M
| $1.44M | 0.05% |
+353,701
| New | +$1.12M |
2022 Q2
0 quarters
|
|
66
DELISTED
Mersana Therapeutics
MRSN
| $1.44M | 0.05% |
12,438
-625
| -5% | -$58.8K |
2022 Q1
1 quarter
|
|
|
CNTA
67
DELISTED
Centessa Pharmaceuticals
CNTA
| $1.42M | 0.05% |
292,320
-162,225
| -36% | -$1.04M |
2021 Q2
4 quarters
|
|
68
DELISTED
Adverum Biotechnologies
ADVM
| $1.26M | 0.04% |
104,670
| – | – |
2021 Q4
2 quarters
|
|
69
DELISTED
Kronos Bio
KRON
| $1.19M | 0.04% |
326,780
| – | – |
2020 Q4
6 quarters
|
|
|
TMPM
70
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
| $993K | 0.03% |
100,000
| – | – |
2021 Q1
5 quarters
|
|
|
EUCRW
71
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
| $660K | 0.02% |
+66,666
| New | +$10.7K |
2022 Q2
0 quarters
|
|
|
FLACW
72
DELISTED
Frazier Lifesciences Acquisition Corporation Warrant
FLACW
| $658K | 0.02% |
66,665
| – | – |
2021 Q2
4 quarters
|
|
|
PRDS
73
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $614K | 0.02% |
200,000
| – | – |
2021 Q1
5 quarters
|
|
74
Praxis Precision Medicines
PRAX
$6.82B
| $515K | 0.02% |
+14,007
| New | +$1.49M |
2022 Q2
0 quarters
|
|
|
OMEG
75
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
| $493K | 0.02% |
50,000
| – | – |
2021 Q1
5 quarters
|
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q2 2022 Portfolio in Review
As of Q2 2022, EcoR1 Capital held 101 positions worth $2.9B, down 9.4% from $3.2B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
EcoR1 Capital deployed $207M of net new capital in Q2 2022, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Alector, an estimated $16.8M trimmed.
- EcoR1 Capital's largest Q2 2022 buy was Seagen Inc. Common Stock: 1,008,628 shares worth $178M.
- EcoR1 Capital added most to Arvinas in Q2 2022, an estimated $81.3M increase.
- EcoR1 Capital's biggest Q2 2022 reduction was Alector, cutting an estimated $16.8M.
- EcoR1 Capital fully exited Arcus Biosciences in Q2 2022, selling an estimated $103M.
- EcoR1 Capital's ten largest holdings make up 61% of its $2.9B portfolio in Q2 2022.
- EcoR1 Capital opened 14 new positions and closed 21 in Q2 2022.
- EcoR1 Capital's portfolio value fell 9.4% quarter-over-quarter to $2.9B.
Based on EcoR1 Capital's 13F filing for Q2 2022, filed 15 Aug 2022.